Clinical Trials Logo

Gynecologic Cancer clinical trials

View clinical trials related to Gynecologic Cancer.

Filter by:

NCT ID: NCT03292328 Completed - Breast Cancer Clinical Trials

Yoga for Symptoms of Nerve Damage Caused by Chemotherapy

Start date: September 18, 2017
Phase: N/A
Study type: Interventional

Some types of chemotherapy used to treat breast cancer can cause damage to nerves with symptoms like tingling, numbness, muscle weakness, and pain in the hands and feet that can last and can affect functioning. The purpose of this study is to find out the effects of yoga on reducing symptoms caused by such nerve damage.

NCT ID: NCT03258307 Completed - Gynecologic Cancer Clinical Trials

Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Pre-post Omentectomy

Start date: February 1, 2017
Phase: N/A
Study type: Interventional

Omentum is adipose tissue lying under inner anterior wall Omentectomy is routine procedure in treatment of gynecological malignancy especially ovarian cancer and some advanced stage endometrial cancer. Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone secrete from adipose tissue. These regulate matabolic process. We aimed comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone levels derivated from adipose tissue pre-postoperatively in patient diagnosed with gynecological malignancy performed omentectomy or not

NCT ID: NCT03245788 Completed - Breast Cancer Clinical Trials

Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study

Start date: February 15, 2017
Phase: N/A
Study type: Interventional

The Stanford Cancer Center is undertaking a Transformation Initiative in order to improve the quality of care and care coordination across the continuum of care. The newest innovation is to introduce lay navigators to specified high-need patients. The larger goal of the project is to assess whether lay navigators can address non-clinical patient needs in a timely fashion and appropriately connect them with their clinical team when warranted. It is expected that proactive interaction with patients will decrease patient anxiety/stress related to their cancer and facilitate higher patient engagement and improved management of physical, social,and emotional health. For the pilot project, the smaller goal is to understand: how lay navigator time is used; the types and frequency of issues brought up by patients; resources that patients are given or referred to; type and frequency of mode of contact with patients; and patients' acceptance of navigators based on refusal. An electronic intake form will be used to collect this information so that data can be analyzed regularly to inform changes to the navigator program as needed.

NCT ID: NCT03200639 Completed - Physical Activity Clinical Trials

Cachexia in Gynecological Cancer and the Preventive Role of Weight Training

Start date: May 30, 2015
Phase: N/A
Study type: Interventional

The study aim was to compare the effectiveness of combined training (CT; aerobic + resistance exercises) and high-intensity interval body weight training (HIITBW) on body composition, metabolic and inflammatory profile, physical function and quality of life in older women with gynecological and breast cancer and their pair-matched controls (older women with no cancer). The hypothesis of the present clinical trial is that HIITBW is effective as well as CT for improvements on body composition, metabolic and inflammatory profile, physical function and quality of life in older women with gynecological and breast cancer.

NCT ID: NCT03158636 Completed - Gynecologic Cancer Clinical Trials

Profiling of Oncology Patients as Part of Clinical Care and Research

PROSPER
Start date: September 1, 2016
Phase:
Study type: Observational [Patient Registry]

The era of precision medicine is an exciting time for clinicians, scientists and patients alike. The increasing appreciation and identification of specific mutations that drive cancers, leaves us on the threshold of a new era in which biomarkers will be used to direct targeted agents to only those patients most likely to respond. The potential medical and scientific benefits of such a personalised approach to cancer therapy are immense. However, a number of barriers challenge successful implementation of this approach of which spatial and temporal heterogeneity are a major concern. Gynaecological cancers are a major cause of mortality and morbidity internationally. In Auckland 150 new patients with ovarian, endometrial or cervical cancer are seen by a medical oncologist each year. In general, when these diseases recur, there are few effective therapeutic options and prognosis is poor. Better therapeutic targets and treatments are an unmet need across these tumour types with treatment paradigms still based upon platinum based therapy. PROSPER (Profiling of Oncology Patients as part of Clinical care and Research) will investigate the evolution of gynaecological cancers over time and in response to treatment to develop better biomarkers to guide treatment decisions and ultimately improve patient outcomes. Biopsies at relapse will be collected and profiled with a 580 cancer gene panel. Circulating tumour DNA will be collected and analysed alongside biopsies as a potential non-invasive alternative. Linking genomic and clinical data will allow us to learn more to begin to change our paradigm of care.

NCT ID: NCT02583815 Completed - Breast Cancer Clinical Trials

Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)

PAMCap
Start date: August 2015
Phase:
Study type: Observational

This is an open label feasibility pilot study of commercially available physical activity monitoring devices in patients receiving systemic therapy at the Harold Simmons Cancer Center, UT Southwestern Medical Center.

NCT ID: NCT02459301 Completed - Gynecologic Cancer Clinical Trials

A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies

Start date: September 17, 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.

NCT ID: NCT02366871 Completed - Clinical trials for Venous Thromboembolism

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

Start date: April 28, 2015
Phase: Phase 2
Study type: Interventional

The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous enoxaparin 40 mg once a day (QD) for 28 days post surgery.

NCT ID: NCT02108457 Completed - Gynecologic Cancer Clinical Trials

[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers

Start date: February 2014
Phase:
Study type: Observational

The purpose of this study is to determine the effect of specific bone marrow maps developed with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment, one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take place in the Department of Radiation Oncology.

NCT ID: NCT02069171 Completed - Gynecologic Cancer Clinical Trials

Cross-sectional and Questionnaire Study for Leg Lymphedema

Start date: June 2012
Phase: N/A
Study type: Observational

The purpose of this study is to identify the incidence,feature,clinical significance for leg lymphedema after gynecologic cancer treatment.